Contributions
Abstract: P445
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - MS and infections
Different infectious agents have been considered in multiple sclerosis (MS) aetiology. Foremost among them are viruses, particularly those belonging to the herpesviridae family, with the Epstein-Barr virus (EBV) as the prime candidate. One hypothesis is that late EBV infection increases the risk for MS, supported by the link between infectious mononucleosis and MS risk. In this project the intention was to identify biobank samples drawn at a younger age compared to previous prospective MS biobank studies - with the aim to study risk factors in samples drawn at the pathophysiological onset of MS, which presumably is during childhood-adolescence.
In this study we had access to serum samples drawn before the age of 40 from 488 cases that later developed MS with relapsing onset, and 488 matched controls. The presence of antibodies (seropositivity) against several viruses was determined using a Luminex assay. Based on age at sample draw, the study population was divided into three age strata: 0-20 (n=188), 20-25 (n=294) and above 25 years (n=494). Odds ratio (OR) was calculated using matched logistic regression analysis in SPSS.
Seropositivity against EBV was associated with a decreased risk for MS (OR=0.48; 95% CI: 0.23-0.98) in the 0-20 year category. Seropositivity against another virus was associated with an increased risk for MS (OR=2.5; 95% CI: 1.3-4.7 and OR=2.6; 95% CI: 1.6-4.3 in the 0-20 and 20-25 year categories).
Viral serologies analysed in presymptomatic samples drawn during the presumed pathophysiological onset of MS reveal a new pattern for EBV, showing that MS is associated with late EBV infection. Also shown was that MS is strongly associated with another virus, previously not established in MS pathogenesis, the name of which will be disclosed at the meeting.
Disclosure: Martin Biström: nothing to disclose.
Peter Sundström: has received honoraria from BiogenIdec for serving as a member of a stipend committee.
Oluf Andersen: nothing to disclose
Maria Hortlund: nothing to disclose
Daniel Jons: nothing to disclose
Lucia Alonso-Magdalena: has received unrestricted grant from Novartis and speaking fees from Biogen, Merck Serono. Served on advisory board for Biogen, Merck Serono.
Izaura Lima Bomfim: nothing to disclose
Jesse Huang: nothing to disclose
Ingrid Kockum: has received honoraria for lecture from Merck Serono.
Tomas Olsson: has received compensation for lectures and /or advisory boards, or unrestricted MS research grants from Biogen, Allmiral, Novartis, Genzyme, Astrazeneca and Merck.
Tim Waterboer: nothing to disclose
Rasmus Gustafson: nothing to disclose
Elin Engdahl: nothing to disclose
Anna Fogdell-Hahn: has received funding and speaking honoraria from Biogen Idec and Pfizer.
Abstract: P445
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - MS and infections
Different infectious agents have been considered in multiple sclerosis (MS) aetiology. Foremost among them are viruses, particularly those belonging to the herpesviridae family, with the Epstein-Barr virus (EBV) as the prime candidate. One hypothesis is that late EBV infection increases the risk for MS, supported by the link between infectious mononucleosis and MS risk. In this project the intention was to identify biobank samples drawn at a younger age compared to previous prospective MS biobank studies - with the aim to study risk factors in samples drawn at the pathophysiological onset of MS, which presumably is during childhood-adolescence.
In this study we had access to serum samples drawn before the age of 40 from 488 cases that later developed MS with relapsing onset, and 488 matched controls. The presence of antibodies (seropositivity) against several viruses was determined using a Luminex assay. Based on age at sample draw, the study population was divided into three age strata: 0-20 (n=188), 20-25 (n=294) and above 25 years (n=494). Odds ratio (OR) was calculated using matched logistic regression analysis in SPSS.
Seropositivity against EBV was associated with a decreased risk for MS (OR=0.48; 95% CI: 0.23-0.98) in the 0-20 year category. Seropositivity against another virus was associated with an increased risk for MS (OR=2.5; 95% CI: 1.3-4.7 and OR=2.6; 95% CI: 1.6-4.3 in the 0-20 and 20-25 year categories).
Viral serologies analysed in presymptomatic samples drawn during the presumed pathophysiological onset of MS reveal a new pattern for EBV, showing that MS is associated with late EBV infection. Also shown was that MS is strongly associated with another virus, previously not established in MS pathogenesis, the name of which will be disclosed at the meeting.
Disclosure: Martin Biström: nothing to disclose.
Peter Sundström: has received honoraria from BiogenIdec for serving as a member of a stipend committee.
Oluf Andersen: nothing to disclose
Maria Hortlund: nothing to disclose
Daniel Jons: nothing to disclose
Lucia Alonso-Magdalena: has received unrestricted grant from Novartis and speaking fees from Biogen, Merck Serono. Served on advisory board for Biogen, Merck Serono.
Izaura Lima Bomfim: nothing to disclose
Jesse Huang: nothing to disclose
Ingrid Kockum: has received honoraria for lecture from Merck Serono.
Tomas Olsson: has received compensation for lectures and /or advisory boards, or unrestricted MS research grants from Biogen, Allmiral, Novartis, Genzyme, Astrazeneca and Merck.
Tim Waterboer: nothing to disclose
Rasmus Gustafson: nothing to disclose
Elin Engdahl: nothing to disclose
Anna Fogdell-Hahn: has received funding and speaking honoraria from Biogen Idec and Pfizer.